Search

Displaying results 5301 - 5310 of 7018 in total
  1. Drug

    LIS-1

    go.drugbank.com/drugs/DB18388
    Experimental

    LIS-1 is an immunoglobulin G (IgG) polyclonal antibody that binds to human T cells.

  2. Drug

    RGG0853

    go.drugbank.com/drugs/DB18669
    Experimental

    RGG0853 is an E1A lipid complex, a repressor gene complexed with a cationic lipid vector.

  3. Drug

    DA-697b

    go.drugbank.com/drugs/DB06001
    Experimental

    DA-967b is an investigational antiplatelet agent that inhibits collagen and ristocetin-mediated platelet activation.

  4. Drug

    Resiquimod

    go.drugbank.com/drugs/DB06530
    Investigational

    It is also being studied to find out if adding it to a tumor vaccine improves the antitumor immune response. It is a type of imidazoquinoline and a type of immunomodulator. … A substance being studied in the treatment of some types of skin cancer. When put on the skin, resiquimod causes some immune cells to make certain chemicals that may help them kill tumor cells.

  5. Drug

    Pilaralisib

    go.drugbank.com/drugs/DB11772
    Investigational

    Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K).

  6. Drug

    ATI-1013

    go.drugbank.com/drugs/DB18185
    Investigational

    ATI-1013 is a fully human nicotine-specific monoclonal antibody.

  7. Drug

    VGA039

    go.drugbank.com/drugs/DB18385
    Investigational

    VGA039 is an IgG4 monoclonal antibody directed against protein S.

  8. Drug

    CTX130

    go.drugbank.com/drugs/DB18627
    Investigational

    CTX130 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD70 antigen.

    Synonyms: Allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting CD70 antigen
  9. Drug

    AG-24322

    go.drugbank.com/drugs/DB13035
    Investigational

    AG-024322 has been used in trials studying the treatment of Neoplasms and Lymphoma, Non-Hodgkin.

  10. Drug

    CY301

    go.drugbank.com/drugs/DB06382
    Experimental

    CY301 (Simplivir) is an investigational gene silencing compound developed by CytoGenix for the treatment of HSV.